MarketPeel
Insider Trading Intelligence
SN

Sean P. Nolan

TSHA
CHIEF EXECUTIVE OFFICER · TAYSHA GENE THERAPIES, INC. · CIK 0001569926
FILING MIX · LIFETIME85%/15%
BUYS
22
SELLS
4
TOTAL VALUE
$2.16M
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
2,934,438
AVG SELL PX
$4.72
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Sean P. Nolan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+100.00%+3.75%+0.63%+3.12%+0.93%
14d4+100.00%+17.07%+0.95%+16.12%-0.18%
30d4+75.00%+23.05%+0.13%+22.92%+11.77%
60d4+75.00%-5.35%-2.87%-2.48%-5.72%
90d4+0.00%+5.40%+3.64%+1.76%+3.00%
180d4(2 pending)+0.00%-22.24%+14.28%-36.52%-36.52%
1y4(2 pending)+50.00%-34.28%+11.31%-45.59%-45.59%
2y4(2 pending)+50.00%-22.13%+26.84%-48.97%-48.97%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TSHA · 2,908,257 shares · as of Jan 26, 2026
0771,5901,543,1792,314,7693,086,358202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 22 buys / 4 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
2,047$90.35$184.9K26,181May 13, 2026May 15, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Executive Officer
41,312$4.61$190.4K2,908,257Jan 26, 2026Jan 27, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Executive Officer
136,789$4.75$649.7K2,949,569Jan 23, 2026Jan 27, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
1,008,0003,086,358Jan 12, 2026Jan 14, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
648,000648,000Jan 12, 2026Jan 14, 2026View →
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
2,882$64.18$185.0K24,134May 13, 2025May 15, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
892,5002,078,358Jan 2, 2025Jan 3, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
892,500892,500Jan 2, 2025Jan 3, 2025View →
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
3,648$47.96$175.0K21,252May 14, 2024May 16, 2024View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
1,184,6881,185,858Jan 2, 2024Jan 4, 2024View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
1,184,6881,184,688Jan 2, 2024Jan 4, 2024View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
466,550466,550Dec 14, 2023Dec 18, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
Chief Executive Officer
444,444$0.90$400.0K1,535,545Aug 16, 2023Aug 16, 2023View →
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
3,835$45.63$175.0K17,604May 16, 2023May 18, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
1,106,1311,106,131Dec 30, 2022Jan 4, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
15,50015,500Jun 17, 2022Jun 22, 2022View →
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
3,056$57.25$175.0K13,769Apr 27, 2022Apr 29, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
15,50015,500Jun 17, 2021Jun 21, 2021View →
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
3,15810,713May 25, 2021May 27, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
1,170$22.35$26.1K1,170May 20, 2021May 24, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
1,6011,091,101Sep 28, 2020Sep 30, 2020View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
1,4700Sep 28, 2020Sep 30, 2020View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
1,000,0000Sep 28, 2020Sep 30, 2020View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
1,089,5001,089,500Sep 28, 2020Sep 30, 2020View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
31,00031,000Sep 23, 2020Sep 25, 2020View →
VTR
VENTAS, INC.
PURCHASEGRANT
Stock grant
5,4247,555May 18, 2020May 20, 2020View →
Other insiders · TSHA
Loading peer insiders…
About this filer
CIK 0001569926
ROLE
Chief Executive Officer
PRIMARY
TSHA
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001569926DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback